Fig. 3: TH5487 murine dosing strategy and weights. | Nature Communications

Fig. 3: TH5487 murine dosing strategy and weights.

From: Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model

Fig. 3

a Mice received intratracheally-administered bleomycin (Bleo; 2.5 U/kg) and were subsequently dosed intraperitoneally (i.p.) with TH5487 (TH), nintedanib (Nin), pirfenidone (Pirf), or dexamethasone (Dex) 1 h post-Bleo administration. Drug treatment occurred five times per week, over the course of 21 days, followed by euthanasia and removal of BALF, plasma, and lung tissues (Bleo n = 15, Bleo/TH n = 14, Bleo/Dex n = 9, Vehicle n = 9, TH only n = 9, Bleo/Pirf n = 7, Bleo/Nin n = 7). Data are presented as means ± SEM (b, c). Data were analyzed using a one-way ANOVA followed by a Dunnett’s post hoc test unless otherwise specified. b Mice receiving Bleo showed weight loss up until day 10, where after those dosed with TH5847 picked up significant amounts of weight compared to the vehicle/bleomycin group. c Representative images of murine lungs (right lobes) removed after 21 days, with lung weights shown alongside, Bleomycin vs Bleo+TH (P < 0.0001), Bleo vs Bleo+Pirf (P < 0.0001), Bleo vs Bleo+Nintedanib (P = 0.0056) (Bleo n = 8, Bleo/TH n = 8, Bleo/Dex n = 5, Vehicle n = 5, TH only n = 5, Bleo/Pirf n = 7, Bleo/Nin n = 7). Source data are provided as a Source data file. Elements of this figure were created with BioRender.com.

Back to article page